摘要
目的研究中药单体冬凌草甲素（ORI）联合组蛋白去乙酰化酶抑制剂丙戊酸钠（VPA）诱导急性早幼粒白血病细胞株HL-60凋亡，探讨其应用于临床的可行性。方法在对数生长期的HL-60细胞中分别加入6—12μmol／L的OR／和0．5—1mmol／L的VPA，采用细胞计数法测定ORI和VPA单独和联合应用时对细胞的生长抑制，并用AnnexinV／PI双标法流式细胞术检测细胞凋亡。结果OR[联合VPA可协同降低HL-60细胞活力，抑制细胞增殖，诱导细胞凋亡，比单独用药凋亡作用更为显著（P〈0．05）。结论ORI和VPA具有协同作用，能高效杀灭白血病细胞。ORI和VPA是一种有望应用于白血病临床治疗的新型生物制剂。
Objective TO investigate the apoptosis-inducing effect of oridonin combined with valproic acid（VPA） on leukemic cell line HL-60 ,and study the feasibility of oridonin combined with VPA to be used in clinical practice. Methods Oridonin of 6-12 μmol/L combined with VPA of 0.5-1 mmol/L were added in exponential growth HL-60 cells respectively. Cell count assays were used to measure the growth inhibitory effect of oridonin combined with VPA or alone. Flow cytometry was used to evaluate apoptosis with Annexin V and propidium iodide （PI） double staining. Results Combined use of oridonin and VPA could synergistically inactivate HL-60 cells,and inhibit the cell proliferation and induce apoptosis in a dose-and time-dependent man- ner （P 〈 0.05）. Conclusion Oridonin has a synergistic effect combined with VPA. Oridonin has a promising prospect in clinical use of leukemia.
出处
《国际肿瘤学杂志》
CAS
2011年第5期390-393,共4页
Journal of International Oncology
基金
国家自然科学基金资助项目（30771103）
山东省自然科学基金资助项目（Y2008C165）
